Investigation of a Cluster of Immunization Stress-Related Reactions after Coronavirus Disease 2019 (COVID-19) Vaccination, Thailand, 2021

Investigation of a Cluster of Immunization Stress-Related Reactions after Coronavirus Disease 2019 (COVID-19) Vaccination, Thailand, 2021

On 28 April 2021, the investigation team of the Department of Disease Control, Ministry of Public Health, was notified of a cluster of people developing neurological symptoms following COVID-19 vaccination in a province in eastern Thailand. We conducted an investigation from 29 April to 20 May 2021...

Full description

Bibliographic Details
Main Authors:	Chayanit Mahasing, Oiythip Yasopa, Chalo Sansilapin, Thanit Rattanathumsakul, Panithee Thammawijaya, Rapeepong Suphanchaimat, Pawinee Doung-ngern
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Vaccines
Subjects:	adverse event following immunization immunization stress-related reaction COVID-19 vaccination CoronaVac
Online Access:	https://www.mdpi.com/2076-393X/10/3/441

Similar Items

Humoral responses to the CoronoVac vaccine in healthcare workers
by: Gokhan Eyupoglu, et al.
Published: (2023-02-01)

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
by: Stevent Sumantri, et al.
Published: (2023-03-01)

Frequency And Factors Associated With Adverse Reactions After Administration of Inactivated COVID-19 Vaccine Among Health Workers
by: Beray Gelmez Taş, et al.
Published: (2023-09-01)

Immune Response to an Inactivated Vaccine of SARS-CoV-2 (CoronaVac) in an Indigenous Brazilian Population: A Cohort Study
by: Laís Albuquerque de Oliveira, et al.
Published: (2024-04-01)

Metabolomics acts as a powerful tool for comprehensively evaluating vaccines approved under emergency: a CoronaVac retrospective study
by: Xinyu Liu, et al.
Published: (2023-07-01)

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
by: Varalee Terbsiri, et al.
Published: (2023-08-01)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
by: Priscilla Ramos Costa, et al.
Published: (2022-10-01)

RESPOSTA CELULAR DE RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
by: Lais Teodoro da Silva, et al.
Published: (2023-10-01)

IMUNOFENOTIPAGEM DE LINFÓCITOS B EM RESPONDEDORES E NÃO RESPONDEDORES ANTICÓRPICOS: ESTUDO EM COORTE DE PROFISSIONAIS DA SAÚDE VACINADOS COM CORONAVAC
by: Juliana Ruiz Fernandes, et al.
Published: (2023-10-01)

Previous Infection with SARS-CoV-2 Correlates with Increased Protective Humoral Responses after a Single Dose of an Inactivated COVID-19 Vaccine
by: Flávia F. Bagno, et al.
Published: (2022-03-01)

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
by: Daniel Leung, et al.
Published: (2023-03-01)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
by: Cheng Cao, et al.
Published: (2023-10-01)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
by: Yuxiao Wang, et al.
Published: (2023-03-01)

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients
by: Yuxin Chen, et al.
Published: (2024-04-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01)

Proteomic and Metabolomic Signatures Associated With the Immune Response in Healthy Individuals Immunized With an Inactivated SARS-CoV-2 Vaccine
by: Yi Wang, et al.
Published: (2022-05-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
by: Eric Yuk Fai Wan, et al.
Published: (2024-09-01)

Assessing the Impact of Primary-Series Infection and Booster Vaccination on Protection against Omicron in Hong Kong: A Population-Based Observational Study
by: Jialiang Jiang, et al.
Published: (2024-09-01)

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China
by: Benchen Rao, et al.
Published: (2024-12-01)

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
by: Yue Yat Harrison Cheung, et al.
Published: (2024-01-01)

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
by: Mine Durusu Tanriover, et al.
Published: (2022-11-01)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
by: Bothamai Dechates, et al.
Published: (2023-03-01)

Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
by: Nungruthai Suntronwong, et al.
Published: (2024-02-01)

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study
by: Celine Sze Ling Chui, et al.
Published: (2022-08-01)

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
by: Suwarti Suwarti, et al.
Published: (2024-08-01)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
by: Alejandro Escobar, et al.
Published: (2022-01-01)

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adultsResearch in context
by: Constanza Méndez, et al.
Published: (2023-05-01)

Side effects of CoronaVac® COVID-19 vaccination: Investigation in North Jakarta district public health center communities in Indonesia
by: Diana Laila Ramatillah, et al.
Published: (2024-05-01)

Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial
by: Weijun Hu, et al.
Published: (2024-01-01)

Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study
by: Ihsan Ates, et al.
Published: (2023-07-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Yun Shan Goh, et al.
Published: (2022-01-01)

Altered expression of miRNA profile in peripheral blood mononuclear cells following the third dose of inactivated COVID-19 vaccine
by: Guanguan Qiu, et al.
Published: (2025-01-01)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
by: Zhujun Jiang, et al.
Published: (2022-05-01)

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
by: Nicolás MS Gálvez, et al.
Published: (2022-10-01)

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality
by: Jialiang Jiang, et al.
Published: (2025-02-01)

How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
by: Juan C. Alzate-Ángel, et al.
Published: (2024-04-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
by: Yue Yat Harrison Cheung, et al.
Published: (2024-06-01)

Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination
by: Almir Ribeiro da Silva Jr, et al.
Published: (2022-02-01)

Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration
by: Camille F. de Oliveira, et al.
Published: (2022-04-01)